Literature DB >> 3720466

HBsAg clearance in chronic active hepatitis B. A possible cause of cryptogenic cirrhosis.

T R Morgan, A G Redeker, S Yamada, M Ashcavai.   

Abstract

Three patients with chronic hepatitis B infection, two with chronic active hepatitis and cirrhosis, and the third with quiescent cirrhosis, cleared HBsAg from their serum and eventually developed anti-HBs. All three were asymptomatic and had nearly normal serum aminotransferases following loss of HBsAg. Liver biopsy revealed cirrhosis in each patient. With the development of anti-HBs, these patients became serologically indistinguishable from patients with a cryptogenic cirrhosis who had prior unrelated exposure to hepatitis B. Remote chronic hepatitis B infection may be a more common cause of cryptogenic cirrhosis than is commonly appreciated.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3720466     DOI: 10.1007/bf01296446

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  16 in total

1.  Viral hepatitis, type B (MS-2-strain). Further observations on natural history and prevention.

Authors:  S Krugman; J P Giles
Journal:  N Engl J Med       Date:  1973-04-12       Impact factor: 91.245

2.  The liver histology and frequency of clearance of the hepatitis B surface antigen (HBsAg) in chronic carriers.

Authors:  R E Sampliner; F A Hamilton; O A Iseri; E Tabor; J Boitnott
Journal:  Am J Med Sci       Date:  1979 Jan-Feb       Impact factor: 2.378

3.  Autoimmune factors in African cirrhosis. Correlation with hepatitis B surface antigen and antibody.

Authors:  F Sadikali; D Doniach
Journal:  Am J Gastroenterol       Date:  1975-12       Impact factor: 10.864

Review 4.  Hepatitis B surface antigen (HBsAg) in the liver of patients with hepatitis; a comparison with serological detection.

Authors:  M B Ray; V J Desmet; J Fevery; J De Groote; A F Bradburne; J Desmyter
Journal:  J Clin Pathol       Date:  1976-02       Impact factor: 3.411

5.  Antibody to hepatitis B core antigen in chronic active hepatitis.

Authors:  P Bories; P Coursaget; A Goudeau; C Degott; P Maupas; J P Benhamou
Journal:  Br Med J       Date:  1978-02-18

6.  Incidence of hepatitis B virus infection in alcoholic liver disease, HBsAg negative chronic active liver disease and primary liver cell cancer in Britain.

Authors:  M F Bassendine; L Della Seta; J Salmeron; H C Thomas; S Sherlock
Journal:  Liver       Date:  1983-04

7.  Evidence that hepatitis B virus has a role in liver-cell carcinoma in alcoholic liver disease.

Authors:  C Bréchot; B Nalpas; A M Couroucé; G Duhamel; P Callard; F Carnot; P Tiollais; P Berthelot
Journal:  N Engl J Med       Date:  1982-06-10       Impact factor: 91.245

8.  Delayed HBsAg clearance in chronic hepatitis B viral infection.

Authors:  K L Lindsay; A G Redeker; M Ashcavai
Journal:  Hepatology       Date:  1981 Nov-Dec       Impact factor: 17.425

9.  State of hepatitis B virus DNA in hepatocytes of patients with hepatitis B surface antigen-positive and -negative liver diseases.

Authors:  C Bréchot; M Hadchouel; J Scotto; M Fonck; F Potet; G N Vyas; P Tiollais
Journal:  Proc Natl Acad Sci U S A       Date:  1981-06       Impact factor: 11.205

10.  Chronic liver disease and hepatitis-B antigen: a prospective study.

Authors:  L Van Waes; J Segers; J Van Egmond; L Van Nimmen; F Barbier; R Wieme; L Demeulenaere
Journal:  Br Med J       Date:  1974-08-17
View more
  4 in total

Review 1.  Immunodiagnosis of viral hepatitides A to E and non-A to -E.

Authors:  G Yang; G N Vyas
Journal:  Clin Diagn Lab Immunol       Date:  1996-05

2.  Spontaneous hepatitis B surface antigen clearance in a long-term follow-up study of patients with chronic type B hepatitis. Lack of correlation with hepatitis C and D virus superinfection.

Authors:  L C Da Silva; C L Madruga; F J Carrilho; J R Pinho; A Saéz-Alquezar; C Santos; L Bassit; C Barreto; L E Fonseca; V A Alves; R Leitão; R Vianna; R A Cardoso; A V França; L C Gayotto
Journal:  J Gastroenterol       Date:  1996-10       Impact factor: 7.527

3.  Phase II study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infection.

Authors:  K H Lai; Y T Tsai; S D Lee; W W Ng; H C Teng; T N Tam; G H Lo; H C Lin; H J Lin; J C Wu
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  Remote development of hepatocellular carcinoma in patients with liver cirrhosis type B serologically cured for HBs antigenemia with long-standing normalization of ALT values.

Authors:  Shogo Okoshi; Masato Igarashi; Takeshi Suda; Hiroshi Iwamatsu; Kohji Watanabe; Kiyoshi Ishihara; Norio Ogata; Minoru Nomoto; Toru Takahashi; Takafumi Ichida; Hitoshi Asakura; Koei Nihei; Isao Kurosaki
Journal:  Dig Dis Sci       Date:  2002-09       Impact factor: 3.199

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.